Evidence map›Paper›PMID 34143342›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Disease severity and response to treatment in Iranian patients with myasthenia gravis.

Farnaz Sinaei, Farzad Fatehi, Shahram Oveis Gharan, Soroush Ehsan, Koorosh Kamali, Shahriar Nafissi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Farnaz SinaeiDepartment of Neurology, Shariati Hospital, Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Farzad FatehiDepartment of Neurology, Shariati Hospital, Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Shahram Oveis GharanDepartment of Neurology, Shariati Hospital, Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Soroush EhsanDepartment of Neurology, Shariati Hospital, Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Koorosh KamaliDepartment of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran.
Shahriar NafissiDepartment of Neurology, Shariati Hospital, Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran. nafisi@sina.tums.ac.ir.ORCID http://orcid.org/0000-0003-4763-4310

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMyasthenia gravis (MG) is a potentially fatal neuromuscular disorder if left untreated. In this study, we tried to address the possible demographic, clinical, and laboratory determinants of severity and outcome in Iranian MG patients over a follow-up period of more than 5 years.

methodsDemographic and diagnostic data (age, age of onset, antibody status, thymus pathology, and duration of the disease) of the patients with MG were extracted. Maximal disease severity and post-intervention status were assessed according to the recommendations of the task force of the Myasthenia Gravis Foundation of America.

resultsIn our series of 146 patients, MG was more severe in older, anti-muscle specific tyrosine kinase (MuSK) positive, and thymomatous patients. Seropositivity to the MuSK antibody and the presence of thymoma determined the need for immunosuppressive drugs. However, the number of patients requiring more than one immunosuppressive was not significantly different among various subtypes.

conclusionsThe overall outcome was favorable in the majority of patients, despite differences in the disease course and severity. In contrary to the previous reports, anti-MuSK positive patients in our series did not need a more vigorous treatment regimen comparing other serologic subtypes of MG.

Indexed as

Myasthenia GravisThymomaThymus NeoplasmsAgedAutoantibodiesHumansIranSeverity of Illness IndexAutoantibodiesMyasthenia gravisOutcomeSeverityTreatment

Identifiers

PMID34143342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.